Prostate Cancer
Prostate Cancer
Advertisement
Emily MenendezLocalized | April 14, 2025
The combination of ADT and radiotherapy can provide quick benefits in patients with intermediate- or high-risk localized PCa.
Read More
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram elucidates the evolving landscape of focal therapy for prostate cancer, emphasizing its ease of adoption.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram describes his post-HIFU surveillance protocol: regular PSA checks, MRI, and biopsies at defined intervals.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram explains the use of HIFU and cryotherapy as primary focal therapy modalities, emphasizing a few treatment options.
Nitin Yerram, MDLocalized | April 14, 2025
Dr. Yerram explains how advances in focal therapy technologies over the past decade have driven increased use and acceptance.
Julian Hong, MDProstate Cancer Diagnostics | April 11, 2025
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Julian Hong, MDProstate Cancer Diagnostics | April 11, 2025
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Carissa Chu, MDProstate Cancer Diagnostics | April 9, 2025
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Scott Tagawa, MD, MS, FACPProstate Cancer | April 4, 2025
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Emily MenendezmHSPC | April 3, 2025
Apalutamide can boost rPFS and OS in patients with mHSPC when diagnosed via conventional imaging.
Amar Kishan, MDRLT | April 3, 2025
Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease.
Emily MenendezCRPC | March 31, 2025
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Emmanuel Antonarakis, MDmCSPC | March 31, 2025
Dr. Antonarakis discusses the differences between PARP1 mRNA expression and other biomarkers used for risk stratification.
Michael Morris, MDmHSPC | March 31, 2025
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Thomas Hope, MDProstate Cancer Diagnostics | March 31, 2025
Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer.
Wolfgang Fendler, MDProstate Cancer Diagnostics | March 31, 2025
Dr. Fendler reviews a multi-center study that used prognostic nomograms to risk-stratify patients based on OS.
Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICDRLT | March 31, 2025
Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes.
Jérémie Calais, MD, PhDRLT | March 26, 2025
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
Louise Emmett, MDProstate Cancer Diagnostics | March 24, 2025
Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...
Phouc T. Tran, MD, PhDProstate Cancer | March 18, 2025
Dr. Tran discusses the benefits of the Decipher score as well as how stratified patients respond differently.
Advertisement
Advertisement